{
  "docId": "019de077-4c75-7299-85f2-8570aa012761",
  "docSlug": "bc27eff688e591dce79cc29b4a79cc4b",
  "documentTitle": "Starboard Value | Activist Presentation Deck | 74 slides",
  "authorId": "starboard-value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 46,
  "pageCount": 74,
  "prevPage": 45,
  "nextPage": 47,
  "slideType": "valuation_table",
  "function": "show_valuation_bridge",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "The chart highlights the discrepancy between management's valuation assumptions and consensus expectations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-4c75-7299-85f2-8570aa012761/46",
  "deckHref": "/decks/019de077-4c75-7299-85f2-8570aa012761",
  "deckJsonHref": "/decks/019de077-4c75-7299-85f2-8570aa012761.json",
  "deckAnchorHref": "/decks/019de077-4c75-7299-85f2-8570aa012761#slide-46",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.235
      },
      "kind": "chart",
      "text": "EV / Peak Sales by Year",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a08b0d8b-ddbc-4e3e-a44e-2c5e45f6e16d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.43,
        "y": 0.5
      },
      "kind": "legend",
      "text": "10 Year Median: 2.4x",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "807b6f57-8843-4df7-9784-f9fd2ecdb7e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "paragraph",
      "text": "Accounting for lower sales expectations highlights the lofty multiples paid by Pfizer.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b09d4961-74fe-4a0a-a8b1-bdeee452ac10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.01,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: Wall Street research and public company presentation. (1) Revenue multiple based upon 2030 sales. (2) Entire Biopharma Industry >$1bn in TEV.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1fa2f4a-da9a-42f3-aa01-c443df9bf61b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Pfizer Appears to Have Significantly Overpaid Based Upon Wall Street's Lower Sales Expectations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "849da667-0201-4704-9007-eeb9b4eff049",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 50,
      "from": 42,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5cfd6c38-7f54-40a4-89ca-d5f3ce72ca30",
      "evidence": "The document highlights the costs of Pfizer's poor capital allocation, including overpaying for acquisitions and losing value.",
      "position": 1,
      "objective": "What are the consequences of Pfizer's poor capital allocation?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}